Table I.
Baseline characteristics for cancer patients treated with immune checkpoint inhibitor
| Characteristic | CirAE (N = 676) | No cirAE (N = 3055) | P value |
|---|---|---|---|
| Sex | |||
| Female | 290 (42.9%) | 1405 (46.0%) | .156 |
| Male | 386 (57.1%) | 1650 (54.0%) | |
| Charlson Comorbidity Index | |||
| Median [IQR] | 3.00 [2.00] | 3.00 [3.00] | <.001 |
| Mean [SD] | 3.30 [2.33] | 3.64 [2.42] | |
| Age at ICI initiation | |||
| Median [IQR] | 65.1 [16.5] | 65.4 [16.4] | .695 |
| Year of ICI initiation | |||
| Median [IQR] | 2017 [2.00] | 2017 [2.00] | .338 |
| Days of follow-up | |||
| Median [IQR] | 913 [952] | 385 [906] | <.001 |
| Race/ethnicity | |||
| White | 634 (93.8%) | 2763 (90.4%) | .008 |
| Asian | 25 (3.7%) | 106 (3.5%) | |
| Black or African American | 8 (1.2%) | 83 (2.7%) | |
| Hispanic | 2 (0.3%) | 21 (0.7%) | |
| Other/unknown | 7 (1.0%) | 82 (2.7%) | |
| Cancer type | |||
| Melanoma | 241 (35.7%) | 522 (17.1%) | <.001 |
| Thoracic | 125 (18.5%) | 1000 (32.7%) | |
| Gastrointestinal | 66 (9.8%) | 350 (11.5%) | |
| Genitourinary | 88 (13.0%) | 303 (9.9%) | |
| Brain/nervous system | 13 (1.9%) | 130 (4.3%) | |
| Breast | 28 (4.1%) | 95 (3.1%) | |
| Gynecologic | 24 (3.6%) | 183 (6.0%) | |
| Head and neck | 60 (8.9%) | 270 (8.8%) | |
| Hematologic | 14 (2.1%) | 147 (4.8%) | |
| Non-melanoma skin | 10 (1.5%) | 25 (0.8%) | |
| Sarcoma | 7 (1.0%) | 30 (1.0%) | |
| ICI type | |||
| PD-1 | 470 (69.5%) | 2350 (76.9%) | <.001 |
| Combination therapy | 120 (17.8%) | 261 (8.5%) | |
| PD-L1 | 65 (9.6%) | 381 (12.5%) | |
| CTLA-4 | 21 (3.1%) | 63 (2.1%) | |
| Mortality status | |||
| Alive | 337 (49.9%) | 1182 (38.7%) | <.001 |
| Deceased | 339 (50.1%) | 1873 (61.3%) | |
CirAE, Cutaneous immune-related adverse event; CTLA-4, cytotoxic T-lymphocyte protein 4; ICI, immune checkpoint inhibitor; IQR, interquartile Range; PD-1, programmed cell death protein 1.